Screener
Summit Therapeutics SMMT Operating Income
Discontinued — last reported Q4 '24
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Summit Therapeutics’s 10-K, filed February 24, 2025.
- Filed
- Feb 24, 2025
- Fiscal year
- FY2024
- Accession
- 0001599298-25-000048
| Line item | Year Ended December 31, 2024 | Year Ended December 31, 2023 | Year Ended December 31, 2022 |
|---|---|---|---|
| Impairment of intangible assets | — | — | 8,468 |
| Total operating expenses | 226,311 | 610,651 | 87,210 |
| Other operating income, net | 313 | 1,001 | 14,416 |
| Operating loss | (225,998) | (609,650) | (72,089) |
| Other income (expense), net | 13,369 | 11,183 | (2,292) |
| Interest expense | (8,686) | (16,461) | (4,401) |
| Net loss | $(221,315) | $(614,928) | $(78,782) |
| Net loss per share: |
Item 16. Report Summary
FAQ
- What is Summit Therapeutics's operating income?
- Summit Therapeutics (SMMT) reported operating income of -$65.61M in Q4 2024.
- How has Summit Therapeutics's operating income changed year-over-year?
- Summit Therapeutics's operating income decreased by 81.2% year-over-year, from -$36.21M to -$65.61M.
- What is the long-term trend for Summit Therapeutics's operating income?
- Over 3 years (2021 to 2024), Summit Therapeutics's operating income has grown at a 37.9% compound annual growth rate (CAGR), from -$86.19M to -$226M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Summit Therapeutics's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude